Daniel J. Dairaghi

Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease

Yu Wang, T. Schall, J. Jaén, 2010, Journal of Pharmacology and Experimental Therapeutics.

Cutting Edge: Identification of a Novel Chemokine Receptor That Binds Dendritic Cell- and T Cell-Active Chemokines Including ELC, SLC, and TECK

Yu Wang, T. Schall, D. Talbot, 2000, The Journal of Immunology.